Join the Voices for Recovery: Celebrating Connections | The Crusader Newspaper Group – The Chicago Cusader

By Keisha L. Jackson

Air Force Veteran and Family Caregiver

September is National Recovery Month. This years theme: Join the Voices for Recovery: Celebrating Connections (https://rm.facesandvoicesofrecovery.org) reminds people in recovery and those who support them that we all have victories to celebrate and things we may wish we had done differently.

Americas Heroes Group celebrates military family caregivers recent guest panelist, Sazha Alexandra Ramos, a Navy veteran in recovery from substance use disorder. Sazha is disrupting the narrative of addiction by getting the message out: people in recovery exist. With nearly six years of recovery, Sazha tells her story so others can learn and be proactive about seeking support services.

Though Sazha used substances as a teenager, it never deterred her from wanting to join the Navy. She believed the military would help her find purpose in life. After graduating high school, Naval boot camp, and A-School (technical training), she was stationed in Italy as an information technology specialist. Sazha was finding her purpose and connection. Six months later, her career capsized after being in an automobile accidenther head hit the window hard and her body suffered trauma.At 19, Sazha was diagnosed with Post Traumatic Stress Disorder, Traumatic Brain Injury, and she lost vision in one eye.

After a month in an Italian hospital, Sazha was transferred to a wounded warrior hospital in the U.S. and placed in barracks with primarily combat, wounded men. She was seen by doctors, neurologists, psychologists, a neuro-ophthalmologist, and was prescribed a lot of medications for physical and emotional pain. It was really tough there, says Sazha. I felt alone and didnt know how to talk to people about what was going on even though I had a therapist.

Sazha hoped to stay in the Navy, but a medical evaluation board determined otherwise. After multiple challenges seeking care with the U.S. Department of Veterans Affairs, she eventually received the treatment she needed.

During four months of seeking sobriety, Sazha lived in a recovery house, which led to her owning/operating two recovery houses; obtaining a Bachelor of Arts in Applied Human Behavior; presenting on a national level for harm reduction, collegiate recovery, and recovery housing; interning with the Association of Recovery in Higher Education; working at the SAFE Project; and for the Veterans Administration, the Chief of Naval Operations Awards Board, and on Capitol Hill for the Wounded Warrior Program that placed veterans in congressional members districts.

Sazha understands there are barriers to accessing treatment for substance use disorder and recognizes that financial support for Black and brown communities is crucial.She is committed to raising one million dollars for people of color and the veteran community to support their recovery housing journey.

If you would like to learn more about this effort, email info@recoveryorganization.com or text GIVE to 83336475.

Keisha L. Jacksonis a 22-year retired Air Force veteran. After caring for her mother who had stage 4 inoperable lung cancer, Keisha started learning about caregiver resources to share with other caregivers.

Looking to Advertise? Contact the Crusader for more information.

Read the original:
Join the Voices for Recovery: Celebrating Connections | The Crusader Newspaper Group - The Chicago Cusader

New Canaan Library Presents Webinar with Bonnie Tsui, author of Why We Swim, Joined by Matthew Busse of New Canaan YMCA – HamletHub

New Canaan Library is pleased to present a live webinar on Thursday, October 1 at 7 pm with Bonnie Tsui, author of Why We Swim, an immersive and eye-opening perspective on swimming and on human behavior itself. Ms.Tsui will be joined in conversation by New Canaan YMCA Director of Pool Operations, Matthew Busse. Please register at newcanaanlibrary.org; Zoom sign in information will be provided upon registration.

Why We Swim is propelled by stories of Olympic champions, a Baghdad swim club that meets in Saddam Husseins palace pool, modernday Japanese samurai swimmers, even an Icelandic fisherman who improbably survives a wintry sixhour swim after a shipwreck.New York Timescontributor Bonnie Tsui, a swimmer herself, dives into the deep from the San Francisco Bay to the South China Sea, investigating what seduces us to water, despite its dangers, and why we come back to it again and again. She offers an immersive, unforgettable, and eye-opening perspective on swimmingand of human behavior itself.

Bonnie Tsuihas written forThe New York Times,The New Yorker,The Atlantic,Outside, and other publications.Why We Swimwas named an Editors Choice/Staff Pick byThe New York TimesBook Review and aBoston GlobeandLos Angeles Timesbestseller. Her previous book,American Chinatown, was the winner of the Asia/Pacific American Award for Literature and aSan Francisco Chroniclebestseller. She lives, swims, and surfs in the San Francisco Bay Area.

MattBusseis the director of pool operations at the New Canaan YMCA. He grew up in New Fairfield, Connecticut, a lake town known for having a deeply rooted culture in aquatic recreation. Matt began his time at the New Canaan YMCA in 2019 as the assistant aquatic director. Matt is currently pursuing his masters degree in recreation administration, focusing on non-profit management. He has been a member of the Impact Panel for the Water Safety Task Force for the Commission on Women, Children, and Seniors, where he stressed the importance of safety around water and parents engaging with their children while in water.

Continued here:
New Canaan Library Presents Webinar with Bonnie Tsui, author of Why We Swim, Joined by Matthew Busse of New Canaan YMCA - HamletHub

CBS Options Year Licensing Deal For Evil, Unicorn To Stream On Netflix – mxdwn.com

Lorin Williams September 23rd, 2020 - 10:38 AM

CBS TV Studios has finalized a deal for its freshman seriesEvilandThe Unicornto stream on Netflix, according to Deadline. For one year, the first seasons of each show will be available to stream on the platform beginning October 1. This will not be an exclusive deal as both series will continue to stream on the networks streaming service CBS All Access, soon to be rebranded as Paramount+.

According to Deadline, CBS is electing this maneuver in attempts to draw new viewership to the two series. Netflix has produced similar success for shows such as The CWsRiverdaleand NBCsGood Girls,with audiences discovering the series after the season one bow. While critics enjoyed bothEvilandUnicorn,the renewed series experienced modest ratings. CBS, which produces both shows, hopes the additional streaming access will boost the titles in wake of second seasons beginning this fall.

Evil, the only genre series on the network, comes from Robert King (The Good Fight, Vertical Limit)and Michelle King (BrainDead, The Good Wife).The series explores the thin line between spirituality and science as an atheist psychologist and Catholic priest-in-training investigate strange occurrences. The twos faith in their beliefs is shaken as they must determine if these afflictions in human behavior are purely mental or demonic. The show stars Katja Herbers (Manhattan, Westworld), Mike Colter (The Following, Luke Cage),Michael Emerson (Lost, Person of Interest), Christine Lahti (Chicago Hope, Law and Order: SVU),and Aasif Mandvi (Avatar: The Last Airbender, Million Dollar Arm).

The Unicornstars Walton Goggins (The Shield, Justified) as a recently widowed father of two who, with the help of family and friends, gets back on his feet and in the dating scene. Created by Mike Schiff (Grounded for Life), Grady Cooper (The Lance Krall Show),and Bill Martin (In with The Flynns), it stands as being one of only two single-camera comedies on CBS, via Deadline.Along with Goggins, the cast includes Omar Benson Miller (CSI: Miami, Ballers),Michaela Watkins (Brittany Runs a Marathon, Casual), Rob Corddry (Hot Tub Time Machine, Childrens Hospital),and Sarayu Rao (I Feel Bad, Blockers).

According to Deadline, CBS boasts some of the most-watched series on Netflix. Neilsen reports state two crime procedurals NCISandCriminal Minds rank among the highest viewed shows on the streaming platform.

Go here to read the rest:
CBS Options Year Licensing Deal For Evil, Unicorn To Stream On Netflix - mxdwn.com

Letter to the editor: ‘Cuties’ degrades girls and women – Canton Repository

The Repository

With politics, the pandemic and disasters in our lives, we are also dealing with our innocent young girls being demoralized. The explicit TV shows, and now a movie called "Cuties" builds and fuels a fire in lust and degradation to girls, women and our future generations.

It only took one glimpse of the movie showinginnocent young girls, inspired by adults, the lowest form of disrespect of any human being.

No word or words can justify what these young girls are taught by exploiting their bodies. So-called adults thinking only of themselves, desperate for attention and social power. They sacrifice young girls, robbing them of their innocence of having a life in the adventures of childhood. Fueling their ego, by using our most vulnerable; not thinking of the consequences they will cause. Our human bodies are unique, clothed with dignity. When did our conduct of character and respect being a female diminish?

We are not less important. We have gifts of kindness, goodness and love. We learned them as children with moral conduct and behavior. A sweetness in our quality of life.

Instead of women showing more of their bodies, they should be respectful in decency with quality in proper behavior. Virtue in moral excellence. When respecting our bodies, we respect others in speech and attire. Etiquette in social behavior.

As women, we do not have to justify muscular power or strength to earn respect. We should be proud of who we are, carrying on the examples of transitions as role models in behavior and ethical principles.

Let these young girls be children to embrace their childhoods. Be a trusting adult in each stage in their life. A lifeline in their stages of development.

God bless our youth and all citizens as we go forth in peace and love. And God bless our United States of America.

JEANIE WILSON, CANAL FULTON

Read the original:
Letter to the editor: 'Cuties' degrades girls and women - Canton Repository

Plant of the Month: Dittany – JSTOR Daily

It is easy to assume that women today have greater reproductive agency than women of the premodern world did. But in many contexts our foremothers actually did seek to exercise agency over their bodies and others through their knowledge and use of medicinal herbs. Perhaps, then, it is not such a stretch to think that they had reproductive options, too.

While for most of history women did not have embryology, ultrasounds, and contraceptive pills, it isnt the case that they had no knowledge of or interest in birth control options. In the early 1990s, historian John M. Riddle argued that in the ancient world and well into the early modern period, most European women had even greater reproductive freedom than we do today. For much of western history, womens agency over reproduction was predicated on knowledge of medicinal herbs like dittany.

For more than 2,000 years, dittany was used as an emmenagogue: a substance to provoke menstruation. In ancient, medieval, and early modern European medicine, regular menstruation was viewed as essential to a womans health. Male physicians offered numerous theories and explanations as to why women menstruated; however, all agreed that missed or delayed periods signaled an imbalance or corruption of the humors. Menstruation was viewed akin to a purge, either as a means to purify the female body or to expel excess bloodand unexpelled menstrual fluid was deemed harmful. Thus, when a woman suffered from delayed menstruation, she turned to known emmenagogic herbs to induce bleeding and return her to health.

Almost all early modern European herbals associated dittany with womens health and identified it as an effective emmenagogue. The most famous of these herbals, Pietro Andrea Mattiolis commentary on Dioscorides, explained that the truest and most potent dittany was found only on the isle of Crete, although two additional varieties with similar virtues were readily available throughout Europe. Of its many uses, this herb was most effective for womens reproductive health, quickening childbirth and easing the pain of labor. Another sixteenth-century herbal, by English botanist John Gerard, stated that dittany of Crete, whether taken in a drink or used in a pessary (vaginal suppository), bringeth away dead children; it procureth the monethly termes [menstruation], and driveth foorth the secondine or the afterbirth. Both herbals are held in the Dumbarton Oaks Rare Book Collection.

As is the case today, delayed or missed menstruation in the early modern world could have been caused by any number of health and environmental factors. Pregnancy, however, was and remains a leading cause. Therefore, argued Riddle, emmenagogues were not only used to restore womens health but were also employed as a means to prevent or terminate unwanted pregnancies. Early modern printed medical books routinely caution women from using emmenagogic herbs while pregnant. For example, a popular 1684 English sex and midwifery manual, Aristotles Masterpiece, instructed women on the precautions to take after they think they have conceived: Let her abstain from all things which may provoke either urine or the courses [menstruation] While intended to help women safeguard a desired pregnancy, this passage also clearly associates inducing menstruation with terminating a pregnancy.

As many historians of science and medicine have concluded, the use of herbs to draw the menses down or provoke menstruation was rather well-known and commonplace among women. For example, a popular sixteenth century Roman herbal, also held in Dumbarton Oakss Rare Book Collection, lists 160 plants capable of provoking menstruation, including three types of dittany. Elite European women in the early modern world would have read printed vernacular medical books such as herbals and collected medicinal recipes, since they were expected to have general medical knowledge in order to fulfill their Christian duties as wives, mothers, and caregivers, both within the home and the community. These women were well versed in the uses of herbs like dittany. Historians postulate that women of lower social classes would have known of the medicinal uses of herbs through the oral tradition that paralleled the written sources and was subsequently largely lost with the professionalization of medicine and the increasing religious and legal restrictions on womens reproduction.

There is evidence, therefore, that early modern European women sought to control menstruation and fertility through herbs. Moreover, historians argue that these practices were socially acceptable and legally permissible due to early modern definitions of pregnancy and abortion that differ from our own. Unlike contemporary science, premodern theories of conception did not distinguish between an embryo and a fetus. Early modern sources also didnt assign full personhood to a fetus. Furthermore, a woman in the early modern world was not pregnant until she declared it. Without our contemporary tests and ultrasounds, detecting pregnancy within the first few months was difficult, and, thus, left up to the mother. Prior to the professionalization of obstetrics, it was women, not male physicians, who determined when a fetus became viable. The quickeningwhen a pregnant woman began to feel or perceive fetal movements, usually between fifteen to seventeen weeks (three to four months)was the most important confirmation of a viable pregnancy and often when women announced it.

This window of time, coupled with the prevalence of emmenagogic herbs in early modern herbals and vernacular medical books, gave premodern women agency over their bodies. If pregnancy was unwanted, women could turn to a herb like dittany to try to provoke menstruation.

But did dittany actually work? There is no scientific evidence of its efficacy as an early-term abortifacient, although there is some evidence that other herbs, such as pennyroyal (with which dittany was often compared) may have that effect. Contemporary research on pennyroyals key active compound, pulegone, has revealed that the plants essential oil does have the potential to produce significant effects on the female reproductive system. But there is some danger involved: Pulegone also makes pennyroyal toxic, and plants in different regions and climates produce varying amounts of it, making proper dosage difficult.

While we have no conclusive evidence on the risks or efficacy of dittany as a form of premodern birth control, we infer from the sources that European women could access this herb and that the prevailing medical literature regarded dittany as an antifertility agent, since controlling menstruation also controlled fertility. Both the historical record and contemporary scientific research support the conclusion that premodern women in the West sought to exercise agency over reproduction, especially in the early stages of pregnancy or before quickening, and that medicinal herbs were central to this endeavor.

Such efforts became increasingly contested and restricted in the course of the nineteenth century. By the mid-1800s in the United States, the American Medical Association had begun pushing to criminalize abortions, while, in 1869, the Catholic church officially prohibited early abortion by canon law.

Fast forward to today, and the reproductive rights of women remain at the center of political discourse in the United States. By investigating the history of herbal emmenagogues and abortifacients, the Plant Humanities Initiative reminds us that women have long sought reproductive agency and illuminates how plants have played a critical role in that story.

Support JSTOR Daily! Join our new membership program on Patreon today.

Read more from the original source:
Plant of the Month: Dittany - JSTOR Daily

Northern N.J.’s University Reproductive Associates offers essential fertility care in a safe environment – Jersey’s Best

Infertility can cause substantial anxiety and raise many difficult questions: What if I cant become pregnant? What will fertility treatment entail? What if all this puts too great a strain on my relationship with my spouse or partner?

Peter McGovern, MD, a board-certified OB/GYN and the co-founder ofUniversity Reproductive Associates (URA), has addressed those questions thousands of times in 25-plus years as a fertility specialist.

There is substantial fear about the process of receiving fertility care, the reproductive endocrinologist said. People dont understand whats possible, and they often feel devastated that they may need medical assistance to achieve something that they think should be basic. Its a big frustration, but people dealing with fertility issues shouldnt lose hope.

In recent months, of course, Dr. McGovern and his colleagues at University Reproductive Associates also have had to address a host of new concerns related to the COVID-19 pandemic. Peoples lives have been upended, and all of us are living in a new reality weve never seen, he said. On top of that, those dealing with fertility issues are wondering how this virus will affect their treatment and pregnancy. COVID essentially has doubled the anxiety some fertility patients already felt.

In response, the physicians, other clinicians and staff at URA have doubled-down on their efforts to address the full range of patients concerns, and to provide essential care in a safe and reassuring environment.

With the pandemics arrival in New Jersey in March, URA enhanced the already rigorous cleaning and sanitization protocols employed at its Hasbrouck Heights, Hoboken and Wayne offices. The practice also adopted other safety approaches recommended by the Centers for Disease Control and Prevention (CDC), state health department, and the American Society for Reproductive Medicine (ASRM). This enabled its physicians to continue to see patients who were at critical points in their care. By the middle of April, as a growing body of scientific evidence provided reassurance about pregnancy and the risks associated with COVID-19, URA began scheduling in-office visits for more patients, in addition to the telehealth appointments it conducts for patients who do not need a physical examination or sonogram at a particular visit.

Today, Dr. McGovern noted, URA has established a new normal that enables patients to receive needed care promptly and safely rather than having to defer their pursuit of pregnancy and their dream of having a child.

There are temperature checks and mandatory face coverings, and many of the other steps you will encounter at all medical facilities. In addition, we have taken several steps specific to the nature of our practice, such as operating a high-technology disinfection system for the air in our embryology labs and using a highly effective, safe disinfectant for vaginal sonogram probes, Dr. McGovern said.

Meanwhile, Dr. McGovern said, the telehealth visits eliminate travel time and inconvenience for patients, while enabling spouses, partners or others to join them for the consultation. He added that based on its experience with telehealth during the COVID outbreak, URA envisions offering the virtual sessions on an ongoing basis. Two other components of URAs approach to providing comprehensive, compassionate care that will continue going forward, just as they did before the pandemic, are the practices provision of free initial consultations for patients without insurance to evaluate their options and the extended support provided to patients throughout the insurance process.

The COVID-19 outbreak has been a time of great anxiety and sorrow. As reproductive endocrinology specialists, we have long experience in helping patients address those emotions. We also are adept at providing fertility care in the setting of other medical conditions and concerns. By employing evidence-based approaches to safeguarding patient health and providing effective treatment, we have been able to help many women become pregnant during these difficult months. Enabling people to experience the joy of having a child is why all of us here do what we do, and while it provides a wonderful sense of accomplishment at any time and in any circumstance, it has been particularly meaningful this year.

For more information on University Reproductive Associates, call (201) 288-6330. Offices in Hasbrouck Heights, Hoboken and Wayne. visitwww.uranj.com.

Continued here:
Northern N.J.'s University Reproductive Associates offers essential fertility care in a safe environment - Jersey's Best

Innovation to Bolster the Sperm Bank Market between 2015 and 2021 – Crypto Daily

Sperm bank is a specialized organization, that collects and stores the sperms collected from human sperm donors for the provision to women who need such sperm to have a pregnancy. Sperm bank also known as cryobank or semen bank, and sperms donated in the bank are known as donor sperm, whereas the process of sperm insertion is known as artificial insemination. It is notable that the pregnancy achieved by using sperms in the sperm bank is similar to natural pregnancy, achieved by sexual intercourse.

The major mechanism involved in the operation of sperm bank underlies the provision of sperms, donated by sperm donors, to the needy women, who, due to various reasons, such as, physiological problems, widow, age and others, are not able to achieve pregnancy. Sperm bank forms the formal contract with sperm donors, usually for the period of 6-24 months, during which he has to produce sperms and donate to the bank. Usually, monetary compensation will be offered to sperm donors. Although, a donor can donate his sperms for more than two years, but, due to laws and regulations of various countries and a potential threat of consanguinity, a contract is made for maximum two years only. A donor produces his sperms in a specialized room, called mens production room. From this, the semen fluid is washed, in order to extract the sperms from other materials present in the semen. In case of frozen storage, a cryoprotectant semen extender is added in the sample. Usually, around 20 vials can be extracted from one sample of semen, collected from a sperm donor. These vials are stored in cryogenically preserved condition, in the liquid nitrogen (N2) tanks. Usually, sperms are stored for the period of around 6 months. However, it can be stored for a longer period of time.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/5330

The services offered by sperm bank includes provision of sperms, donors selection, guiding recipient for selection of donor, sex selection of baby, and sales of sperms. Although, sperm banks play a major role in the women who are not able to achieve pregnancy, due to some controversial issues, such as, use of sperms by lesbian couples and others, government healthcare bodies of various countries imposed strict regulations on the sperm bank. In the U.S., sperm banks are regulated by FDA, and treated as Human Cell or Human Tissue or Human Cell and Tissue (HCT/Ps), in the European Union, it is been regulated by EU Tissue Directive, whereas, in the U.K., it is regulated by Human Fertilization and Embryology Authority.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/5330

The global market for sperm banks is expected to increase in steady manner in the forecast period, due to market growth propellers, such as, increased prevalence of women miscarriage, technological innovations in the sperm storage industry, and growing awareness towards this type of pregnancy. Increased miscarriage rate is one of the major drivers that fuels market growth. According to the study report published by HopeXchange, out of 4.4 million pregnancies carried every year in the U.S., around 1 million pregnancies result into miscarriage. Similarly, due to growing concerns towards such pregnancy that achieved without sexual intercourse is also an important market growth propeller. On the other hand, various governmental regulations, negative mindset towards sperm banks and donor, high cost associated with the operating of sperm bank and limited spread across the various regions of the world are some of the major hurdles in the market growth.

Major players operating in the market includes Cryos International Sperm Bank, FairFax Cryobank, Androcryos, New England Cryogenic Center, Inc. and others.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/5330

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

See the original post here:
Innovation to Bolster the Sperm Bank Market between 2015 and 2021 - Crypto Daily

COVID-19: Can we tackle the root cause of inflammation? – Medical News Today

Researchers in Spain and the United States have proposed that an existing drug may help prevent an excessive, life threatening immune reaction to SARS-CoV-2 in susceptible individuals.

In people with severe COVID-19, which is the disease that SARS-CoV-2 causes, hyperinflammation exacerbates breathing difficulties and can lead to potentially fatal acute respiratory distress syndrome.

However, there is good evidence to suggest that drugs that reduce inflammation, such as the steroid dexamethasone, can save the lives of patients already on ventilators and those receiving supplemental oxygen.

Now, though, scientists at the University of Mlaga in Spain and the University of California, Los Angeles, have proposed a novel way to identify patients at high risk of developing hyperinflammation and prevent it from occurring.

They hypothesize that healthcare providers could give an existing drug to such patients early in the infection to address the root cause of the excessive immune response.

Their proposal appears in the journal Cytokine & Growth Factor Reviews.

Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.

The researchers suggest that initial infection with the virus causes stress at the cellular level. In particular, this is stress involving an organelle within cells called the endoplasmic reticulum (ER).

The ER is where the cell manufactures its proteins. When a virus invades a cell, it hijacks this cellular machinery to make its own proteins.

In 2019, scientists discovered that SARS-CoV, which is the coronavirus that caused the 20022003 SARS outbreak, triggers an inflammatory response by making a particular protein.

Molecules of the protein stress the ER by clumping together. These insoluble aggregates either kill the cells directly or activate the innate immune system.

This branch of the immune system is the first line of defense against pathogens. It deploys signaling molecules called cytokines that recruit immune cells to the site of infection as part of an inflammatory response.

In the new paper, the researchers suggest that ER stress is also a feature of early SARS-CoV-2 infections. They also propose that a drug called 4-phenylbutyric acid (4-PBA), which healthcare providers use to treat urea cycle disorders, could prevent ER stress in COVID-19.

4-PBA acts as a chemical chaperone, stabilizing proteins and preventing them from clumping together.

By preventing ER stress in this way, the researchers say that it reduces the inflammatory response in a range of other conditions, including lung and cardiovascular disease, liver failure, pancreatitis, and diabetic encephalopathy.

They report that they recently developed a 4-PBA treatment for lung disease and tested it successfully in mice. However, they have not yet published their results.

The scientists speculate that people at high risk of developing severe COVID-19 such as older adults and those with cardiovascular conditions, diabetes, or obesity already have underlying ER stress in their cells.

They believe that this makes them especially vulnerable to further ER stress, and the resulting inflammation, if they contract SARS-CoV-2.

When cells are stressed by infection, they call the cytokines, and the more stressed they are, the more persistent they become, provoking this uncontrolled inflammation, explains senior study author Ivn Durn, of the Department of Cell Biology, Genetics, and Physiology at the University of Mlaga.

Hence, one possible treatment for COVID-19 is to reduce cellular stress.

Because 4-PBA is already an approved drug, the authors say that healthcare providers could start using it immediately in patients at high risk of cellular stress and hyperinflammation.

There are people already [living with conditions] that cause cellular stress, and when they [contract] coronavirus, they are more likely to fall ill or die, says Durn.

Therefore, if we know that the patient [has] cellular stress, we can kill two birds with one stone: We can detect susceptibility before infection occurs and know how to treat it in due time.

A protein in the ER called binding immunoglobulin protein (BiP) increases in concentration in response to cellular stress and finds its way into the bloodstream.

The study authors believe that healthcare providers could use the concentration of BiP in the blood to indicate a patients risk of developing hyperinflammation. They could also use it to measure the patients response to treatment with 4-PBA.

However, the authors caution that much more work is necessary to test their proposals.

They write:

It is necessary to do further research to prove the inflammatory component of this model, but our results suggest that 4-PBA treatment could be used to prevent respiratory failure in COVID-19 patients if the ER stress is confirmed to be part of the mechanism.

The team has secured funding to conduct in vivo and in vitro research into the inflammatory response in SARS-CoV-2 infection and the possibility of using 4-PBA as a treatment.

View original post here:
COVID-19: Can we tackle the root cause of inflammation? - Medical News Today

City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy – Business Wire

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that it has licensed intellectual property relating to its pioneering chlorotoxin chimeric antigen receptor (CLTX-CAR) T cell therapy to Chimeric Therapeutics Limited, an Australian biotechnology company.

The therapy is currently being used in a phase 1 clinical trial at City of Hope to treat glioblastoma (GBM), a type of brain tumor. The first patient in the trial was recently dosed; Behnam Badie, M.D., chief of City of Hopes Division of Neurosurgery and The Heritage Provider Network Professor in Gene Therapy, is leading this innovative, first-of-its-kind trial.

Chimeric has acquired the exclusive worldwide rights to develop and commercialize certain patents relating to City of Hopes CLTX-CAR T cells, as well as to further develop the therapy for other cancers.

City of Hope is excited to enter into this agreement with Chimeric as it supports our innovative research in CAR T cell therapy and our commitment to extend these therapies to more patients, particularly those with GBM and other solid tumors that are difficult to treat, said Christine Brown, Ph.D., The Heritage Provider Network Professor in Immunotherapy and deputy director of City of Hopes T Cell Therapeutics Research Laboratory. Chimeric shares our goal of providing effective CAR T cell therapies to more patients with current unmet medical needs.

Led by Brown and Michael Barish, Ph.D., chair of City of Hopes Department of Developmental and Stem Cell Biology, and Dongrui Wang, Ph.D., a recent graduate of City of Hopes Irell & Manella Graduate School of Biological Sciences, the team developed and tested the first CAR T cell therapy using CLTX, a component of scorpion venom, to direct T cells to target brain tumor cells. The research was published this past March in Science Translational Medicine.

Chimeric is excited to join City of Hope in its quest to find more effective cancer therapies. This is an exceedingly rare opportunity to acquire a promising technology in one of the most exciting areas of immuno-oncology today, said Paul Hopper, executive chairman of Chimeric. Furthermore, the CLTX-CAR T cell therapy has completed years of preclinical research and development, and recently enrolled its first patient in a phase 1 clinical trial for brain cancer.

CARs commonly incorporate a monoclonal antibody sequence in their targeting domain, enabling CAR T cells to recognize antigens and kill tumor cells. In contrast, the CLTX-CAR uses a synthetic 36-amino acid peptide sequence first isolated from death stalker scorpion venom and now engineered to serve as the CAR recognition domain.

In this recent study, City of Hope researchers used tumor cells in resection samples from a cohort of patients with GBM to compare CLTX binding with expression of antigens currently under investigation as CAR T cell targets. They found that CLTX bound to a greater proportion of patient tumors, and cells within these tumors.

CLTX binding included the GBM stem-like cells thought to seed tumor recurrence. Consistent with these observations, CLTX-CAR T cells recognized and killed broad populations of GBM cells while ignoring nontumor cells in the brain and other organs. The study team demonstrated that CLTX-directed CAR T cells are highly effective at selectively killing human GBM cells without off-tumor targeting and toxicity in cell-based assays and in animal models.

City of Hope, a recognized leader in CAR T cell therapies for GBM and other cancers, has treated more than 500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world it currently has 30 ongoing CAR T cell clinical trials, including CAR T cell trials for HER-2 positive breast cancer that has spread to the brain, and PSCA-positive bone metastatic prostate cancer. It was the first and only cancer center to treat GBM patients with CAR T cells targeting IL13R2, and the first to administer CAR T cell therapy locally in the brain, either by direct injection at the tumor site, through intraventricular infusion into the cerebrospinal fluid, or both. In late 2019, City of Hope opened a first-in-human clinical trial for patients with recurrent GBM, combining IL13R2-CAR T cells with checkpoint inhibitors nivolumab, an anti-PD1 antibody, and ipilimumab, blocking the CTLA-4 protein.

Both an academic medical center and a drug development powerhouse, City of Hope is known for creating the technology used in the development of human synthetic insulin and numerous breakthrough cancer drugs. Its unique research and development hybrid of the academic and commercial creates an infrastructure that enables City of Hope researchers to submit an average of 50 investigational new drug applications to the U.S. Food and Drug Administration each year. The institution currently holds more than 450 patent families.

"City of Hope is delighted to license this technology to Chimeric, said Sangeeta Bardhan Cook, Ph.D., City of Hope director of the Office of Technology Licensing. We are impressed with the ability of their executive team to push and bring therapies to market expeditiously. At City of Hope, our mission is to transform the future of health care. We believe Chimeric has the vision to offer innovative therapies to cancer patients.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nations Best Hospitals in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

More here:
City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy - Business Wire

Shared protein fingerprint could simplify treatment of common inherited heart disease – Newswise

Newswise MADISON, Wis. Hypertrophic cardiomyopathy is the most common inherited heart disease, marked by an abnormally thickened heart muscle that can obstruct blood flow and lead to sudden death in young adults.

A dizzying array of over 1,400 genetic mutations can lead to the disease, puzzling doctors on how to treat so many unique varieties. But in new research, University of WisconsinMadison scientists discovered that many different genetic mutations result in surprisingly similar changes to heart muscle proteins in patients with the most severe manifestations of hypertrophic cardiomyopathy. This shared protein fingerprint suggests that shared treatments could treat the disease.

This could be good news for doctors treating obstructive hypertrophic cardiomyopathy patients, because our data suggest theres a convergent pathway in these patients, allowing development of treatments that generally target patients with severe obstruction from their cardiomyopathy instead of targeting a patient's individual genetic mutations, says Ying Ge, a professor of cell and regenerative biology and chemistry at UWMadison who headed the new study.

Ge and an international collaboration of researchers published their findings the week of Sept. 21 in the Proceedings of the National Academy of Sciences. UWMadison graduate students Trisha Tucholski and Wenxuan Cai led the work, which analyzed in detail the protein signatures of diseased and normal hearts using advanced protein-measurement technology.

The team collected samples of diseased heart tissue from 16 patients who underwent corrective surgery to fix impaired blood flow in their hearts. Hypertrophic cardiomyopathy in eight of these patients was due to eight distinct mutations across two genes; for the other eight patients, the disease-causing mutations were unknown. Proteins from the diseased heart samples were compared to those from healthy donor hearts.

Despite the variation in underlying genetic mutations, Ges team discovered a general pattern in hearts from patients with the disease. For example, many key muscle proteins from diseased hearts had fewer molecular tags known as phosphates. While the exact consequence of having fewer phosphates is unknown, its likely that these altered proteins contribute to a general state of dysregulation in the heart, leading to the thickened muscle characteristic of the disease.

The findings reinforce that genetic mutations arent always enough to explain diseases, says Ge. The proteins those genes encode have the ultimate impact on health, and the bodys proteins can be altered in subtle but consequential ways during disease.

When we first performed these experiments, this similarity at the protein level was quite surprising to us because it is generally expected that different mutations could lead to different changes in the proteins, says Ge. But in reality, these results make sense, because when the patients with this disease present to the hospital for surgery, their hearts exhibit similar dysfunction.

The results are still preliminary. Ges group wants to expand to study hundreds of additional patients with a wide array of underlying hypertrophic cardiomyopathy mutations to see if the similar protein fingerprint trend holds. They also plan to study heart stem cells with disease-causing mutations in an effort to study early stages of the disease, which isnt possible with human patients.

But with additional research, this kind of in-depth analysis of protein fingerprints could guide future treatments.

This data opens the door with evidence showing that protein-level changes might be a better reflection of the patients disease than their genes, and if we can examine patients' samples at the protein level, that could help us provide precision-medicine treatments, says Ge.

This work was supported in part by the National Institutes of Health (grants R01 HL096971, R01 GM117058, GM125085, HL109810, S10 OD018475, T32 GM008505, T32 GM008688, R01 HL129798, U01 HL134764, and R01 HL139883) and the National Science Foundation (grant EEC-1648035).

Excerpt from:
Shared protein fingerprint could simplify treatment of common inherited heart disease - Newswise